Microcap Ledger Exagen Inc. $XGN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Vista, CA
- Fiscal year end
- December 31
- Shares outstanding
- 24,225,339 [10-Q 2026-08-04]
What the company doesAI summary of filing
Exagen Inc. is a medical technology company that designs, develops and commercializes diagnostic testing products under its AVISE brand for the differential diagnosis, prognosis and monitoring of autoimmune and rheumatic diseases, including systemic lupus erythematosus and rheumatoid arthritis. The company's flagship product, AVISE CTD, represented 91% of revenue in 2025 and generated record annual revenue of $66.6 million, an increase of approximately 19.7% compared to 2024, driven by increased testing volume and average selling price. Exagen operates as a revenue-generating company with a specialized sales force targeting approximately 6,000 U.S. rheumatologists, and generates revenue primarily through third-party payor reimbursement and patient billing arrangements. The company is also developing pipeline products including tests for lupus nephritis, SLE disease activity, rheumatoid arthritis disease activity, kidney damage biomarkers and myositis biomarkers. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $37.25M | −$7.16M | −$6.43M | $24.59M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | $66.58M | −$19.95M | −$13.63M | $32.22M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $55.64M | −$15.12M | −$13.28M | $22.04M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$3.21M
- Cash runway Estimate
- ~22.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 17,637,278 | [10-Q 2024-11-12] |
| 2025-03-07 | 17,898,098 | [10-K 2025-03-11] |
| 2025-05-01 | 18,002,416 | [10-Q 2025-05-05] |
| 2025-07-24 | 22,003,641 | [10-Q 2025-07-29] |
| 2025-10-31 | 22,663,099 | [10-Q 2025-11-04] |
| 2026-03-06 | 24,053,058 | [10-K 2026-03-10] |
| 2026-05-06 | 24,159,839 | [10-Q 2026-05-11] |
| 2026-07-30 | 24,225,339 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2025-06-20; declared effective 2025-07-02 [S-3 2025-06-20]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-01 | Black Jeffrey G. | sell | 20,614 | $7.22 | [4 2026-09-02] |
| 2026-09-01 | Black Jeffrey G. | grant | 1,571 | $3.02 | [4 2026-09-02] |
| 2026-03-12 | Black Jeffrey G. | grant | 75,000 | $3.16 | [4 2026-03-16] |
| 2026-03-12 | Aballi John | grant | 150,000 | — | [4 2026-03-16] |
| 2026-02-27 | Black Jeffrey G. | grant | 1,511 | $3.08 | [4 2026-03-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Results of operations |
| 2026-06-09 | 8-K | Shareholder vote results |
| 2026-05-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-04-27 | DEF 14A | Proxy statement |
| 2026-04-23 | 8-K | Director or officer change |
| 2026-03-10 | 10-K | Annual report |
| 2026-03-10 | 8-K | Results of operations |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $XGN
Email me when Exagen Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.